New 'Sandwich' strategy aims to stop leukemia relapse

NCT ID NCT05470777

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new treatment plan for adults with B-cell acute lymphoblastic leukemia (B-ALL) who cannot or choose not to have a donor stem cell transplant. The approach uses a 'sandwich' strategy: first, patients receive two types of CAR T-cells (targeting CD22 and CD19), then their own stem cells are collected and returned after high-dose chemotherapy, followed by another round of CAR T-cells. The goal is to see if this combination is safe and reduces the risk of the cancer coming back. The trial involves 37 participants and is currently active but no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CD22/CD19 CAR T-cells and autologous stem cell transplant

What this could lead to

If successful, this approach could lower the chance of leukemia returning after initial treatment, offering a longer period without disease.

What could go wrong

This is a small, early-phase trial with only 37 participants, so results may not apply to everyone. There are risks from CAR T therapy and stem cell transplant, including severe side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia Burkitt lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, 215006, China